Table 8: Opioid Equianalgesic Table (Stanford College of Medicine, 2022)
Approximate Equianalgesic Oral Dose
Approximate Equianalgesic Intravenous Dose
Medication Morphine
Conversion Factor to Oral Morphine Parenteral morphine is 3 times as potent as oral morphine. Oral oxycodone is roughly 1.5 times more potent than oral morphine. Oral hydrocodone is roughly 1.5 times more potent than oral morphine. Oral hydromorphone is about 4 to 7 times as potent as oral morphine. Parenteral hydromorphone is 20 times as potent as oral morphine. Transdermal fentanyl is ~80 times as potent as oral morphine. (See Table 7 to convert morphine to fentanyl transdermal patches.)
30 mg
10 mg
Oxycodone
20 mg
Hydrocodone
20 to 30 mg
Hydromorphone
7 mg
1.5 mg
Fentanyl
100 mcg (0.1 mg) 15 mcg/hour
Methadone
Variable
Variable
Tramadol Codeine
300 mg
0.1
200 mg
0.15
Meperidine
300 mg of oral meperidine
75 mg of parenteral meperidine
Oral morphine is about 10 times more potent than oral meperidine and about twice as potent as parenteral meperidine (mg for mg).
*Note: To convert to ER/LA opioids, see conversion factors listed in Table 7. Calculation of equianalgesic dosages Follow these three steps to calculate equianalgesic dosages when changing to a different opioid analgesic: Step 1 : Calculate the total daily dose of the current opioid. Step 2 : D etermine the equianalgesic dose using the appropriate conversion factor or ratio. Step 3 : R educe the new opioid analgesic dose by 33% to
Step 2: Determine the equianalgesic dose using the appropriate conversion factor or ratio. Oral hydromorphone to oral morphine conversion ratio: 4 28 mg hydromorphone/day × 4 = 112 mg morphine/day OR 28 mg hydromorphone equianalgesic dose of morphine 7.5 mg = 30 mg Equianalgesic dose of morphine/day = 112 mg Step 3: Reduce dose by 33% to 50% to account for cross-tolerance; determine a new regimen based on available dosage forms of the new opioid. Total daily dose of morphine = 74 to 56 mg/day New regimen: MS Contin 30 mg every 12 hours (Total morphine dose = 60 mg/day) NP Consideration: Opioid equianalgesic dose conversions are not the same as the MME conversions. Do not use MME factors to convert between opioid medications, as this may lead to serious adverse effects, including respiratory depression, overdose, and death. versus risks of opioid treatment to determine if changes or discontinuation of opioid therapy are required. Functional improvements may be incremental and occur over months or years. Further, some patients who begin showing solid progress may plateau. In these cases,
50% to account for cross-tolerance, dosing ratio variation, and patient variability. Determine a new regimen based on the available dosage form(s) of the new opioid. Clinical Case Example CD is a 32-year-old female with chronic pain. She is taking Exalgo 16 mg once daily and hydromorphone immediate- release 4 mg three times daily for breakthrough pain. The patient should be transitioned to MS Contin due to insurance issues. What dose of MS Contin should be started? Step 1: Calculate the total daily dose of the current opioid. Exalgo 16 mg once daily + hydromorphone immediate- release 4 mg three times daily = 28 mg/day hydromorphone Monitoring adults receiving chronic opioid therapy Ongoing patient monitoring and reiterating vital components of the agreed-upon treatment plan are necessary during long- term therapy with opioids. In addition, continue to assess patient-specific improvement
Page 68
EliteLearning.com/Dental
Powered by FlippingBook